⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CNTA News
Centessa Pharmaceuticals plc American Depositary Shares
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
globenewswire.com
CNTA
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
globenewswire.com
CNTA
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
globenewswire.com
CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
CNTA
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
globenewswire.com
CNTA